Boston, MA – April 2, 2025 – CellCentric, a clinical stage biotechnology company, today announces the opening of a new office in Boston, Massachusetts marking a significant step in expanding its presence in the United States. This will increase the company’s drug development capacity, progressing its novel drug treating multiple myeloma, inobrodib.
Located in Burlington, just outside of Boston, the new site will enhance the company’s ability to access talent and foster further clinical collaborations, as the company accelerates towards registration studies for its first-in-class oral drug.
Andy Fergus, Chief Development Officer at CellCentric, commented: “Boston’s status as a global hub for biotechnology and pharmaceutical innovation makes it the ideal location to further advance inobrodib’s development. Our new office will serve as key additional hub for our international operations as we convene expertise from across the globe to address an unmet need in the multiple myeloma community.”
In conjunction with the office opening, CellCentric has strengthened its leadership significantly in recent months. The bolstered team has been involved with more than 50% of all late-stage development and targeted approved therapies for multiple myeloma. The development of inobrodib is being led by Chief Strategy Officer Naseer Qayum (formerly of Roche, J&J, and AbbVie) and Chief Development Officer Andy Fergus (formerly of Takeda). Both bring deep expertise in advancing novel therapies through to registration.
This expansion into Boston, along with strategic appointments across all levels of the company, demonstrates momentum in advancing inobrodib’s development at pace. Last year the company received significant investment from RA Capital before releasing promising efficacy and safety data at American Society of Hematology (ASH) Annual Meeting.
About inobrodib
Inobrodib is a new type of treatment for people with cancer, and multiple myeloma in particular. It is a small molecule drug that targets p300/CBP, lowering the expression of key cancer drivers, MYC and IRF4. Delivered as an oral capsule, it is easy for patients to take and can be used at home without the need for intensive monitoring. As it has a good safety profile for a drug in this setting, it may be used by those who are unable to access or tolerate other types of treatment. It has the potential to present a lower overall burden on the healthcare system as compared to more complex agents.
About CellCentric
CellCentric is an innovative biotechnology company with offices in the UK and US. The company was spun out from the University of Cambridge, by pioneering developmental biologist Professor Azim Surani FRS, CBE, who wanted to further explore the potential of targeting cell fate control mechanisms.
